Vor Biopharma Inc. (NasdaqGS: VOR)
Health Care · Biotechnology · US
$24.04
+2.91% today · -43.3% 1Y
Vor Biopharma Inc. (NasdaqGS: VOR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.38B and employs 76 people.
Over the last twelve months the share price has lost 43.3%, trading between 6.50 and 50.20.
Tweenvest scores Vor Biopharma Inc. across four factors: quality 22/100. Its strongest factor is quality.
VOR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.38B
- Revenue (TTM)
- —
- P/E
- 1.16
- EPS
- 20.19
- Dividend yield
- —
- Beta (5Y)
- 1.72
- 52-week high
- $50.20
- 52-week low
- $6.50
- Avg volume (3M)
- —
- Shares outstanding
- 59.16M
- Employees
- 76
- Next earnings
- —
About Vor Biopharma Inc.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
- ISIN
- US9290332074
- Founded
- 2015
- Listed since
- Feb 5, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.